|
1. BIOLOGIE
|
|
|
|
2. ETIOLOGIE
|
|
|
|
2.11 ETIOLOGIE - ALIMENTATION
|
|
|
Poor diet may increase risk for preventable cancers [UPI]
|
|
|
|
|
|
More than 80,000 invasive cancers diagnosed in 2015 may be linked to diet-related causes, according to new findings published Wednesday in JNCI Cancer Spectrum. That accounts for 5.2 percent of all cancers in the United States.
|
|
|
|
|
|
|
2.6 ETIOLOGIE - ENVIRONNEMENT
|
|
|
|
|
2.7 ETIOLOGIE - OBÉSITÉ
|
|
|
Ultra-Processed Diet Leads to Extra Calories, Weight Gain [NIH Director's Blog]
|
|
|
|
|
|
Both diets consisted of three daily meals, and volunteers were given permission to eat as much food as they liked. Importantly, a team of dieticians had carefully designed the ultra-processed and unprocessed meals such that they were well matched for total calories, calorie density, macronutrients, fiber, sugars, and salt.
|
|
|
|
|
|
|
3.1 PRÉVENTION - TABAC
|
|
|
|
4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
|
|
|
|
4.1 DÉP., DIAG. & PRONO. - PROSTATE
|
|
|
|
4.10 DÉP., DIAG. & PRONO. - POUMON
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
|
5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
|
|
|
|
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
|
|
|
|
5.17 TRAITEMENTS - RADIOTHÉRAPIE
|
|
|
Proton therapy for cancer lowers risk of side effects [WUSTL]
|
|
|
|
|
|
After controlling for differences between the groups, such as age and additional medical problems, the researchers found that patients receiving proton therapy experienced a two-thirds reduction in the relative risk of severe side effects within 90 days of treatment, compared with patients receiving X-ray radiation therapy.
|
|
|
|
|
|
|
Proton Therapy Lowers Risk of Side-Effects Compared to Conventional Radiation [Penn Medicine]
|
|
|
|
|
|
Importantly, overall survival and disease-free survival were similar between the two groups, suggesting that the reduction in toxicity seen with proton therapy did not come at the cost effectiveness. While researchers say more study is needed, they point out that this study is the best information we have so far as randomized controlled trials continue to prove difficult to complete.
|
|
|
|
|
|
|
5.2 PHARMA
|
|
|
|
No news is bad news for Tocagen [Biopharma Dive]
|
|
|
|
|
|
Tocagen said Tuesday its brain cancer trial has not been able to show so far that a combination therapy of experimental agents Toca 511 and Toca FC extended survival when compared with chemotherapy or Avastin. Investors took the announcement as a sign that the trial is likely to fail, as shares fell 35% Wednesday to a record low.
|
|
|
|
|
|
|
AstraZeneca Offers a Perch to Cancer High Flier Who Stumbled [Bloomberg]
|
|
|
|
|
|
The second day into Jose Baselga’s tenure as head of AstraZeneca Plc’s cancer research, his new boss called him in to discuss a rival company’s drug. Under development by Daiichi Sankyo Co., it represented the latest generation of treatments the researcher had tested earlier in his career. The drug could transform the way doctors look at one of the most common forms of breast cancer, Baselga told Astra Chief Executive Officer Pascal Soriot, who was already thinking about a deal.
|
|
|
|
|
|
|
|
5.2.2 PHARMA - FUSIONS & ACQUISITIONS
|
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
Innovation Strategic Priority Project Report [ICMRA]
|
|
|
|
|
|
There were two areas identified under the umbrella of horizon scanning: analysis of global best practices in horizon scanning methodologies and leveraging from the outcomes of horizon scanning (innovation of products and technologies and required expertise).
|
|
|
|
|
|
|
Drug regulators look to harmonize how they tackle innovation [EndPoints]
|
|
|
|
|
|
The International Coalition of Medicines Regulatory Authorities (ICMRA) recently released a report on how various regulators worldwide are working together to better identify and address future regulatory challenges posed by new categories of therapeutics, like cell and gene therapies, and new tools for drug development, such as artificial intelligence (AI).
|
|
|
|
|
|
|
5.5.4 ASCO (IMMUNOTHÉRAPIES)
|
|
|
|
6.1 OBSERVATION
|
|
|
|
Study shows incidence rates of aggressive subtypes of uterine cancer rising [NIH]
|
|
|
|
|
|
The increasing incidence of nonendometrioid subtypes is not likely explained by the rising prevalence of obesity and changes in use of hormone replacement therapy, as these factors are more strongly associated with the endometrioid subtypes, the rates of which remained more stable over the study period, Dr. Clarke explained.
|
|
|
|
|
|
|
|
6.10 POLITIQUES
|
|
|
|
6.3 ASSOCIATIONS/FONDATIONS
|
|
|
Exposing drug industry funding of UK patient organisations [BMJ]
|
|
|
|
|
|
The hierarchy of funding within each condition area also reflected the industry’s commercial priorities. In neoplasms, multiple myeloma attracted £7 495 729 (35.9%), followed by breast cancer (19.6%); 26 other types of cancer attracted less than 10% of funding. Diabetes received £3 741 181 (57.6%), the most of any endocrine, nutritional, and metabolic disease.
|
|
|
|
|
|
|
6.6 PUBLICATIONS
|
|
|
|
PLOS Journals Now OPEN for Published Peer Review [PLOS Blog]
|
|
|
|
|
|
Peer review history will have its own DOI enabling reviewers to take credit and earn citations for their contributions. If the reviewers have chosen to sign their reviews, their name will also appear on the published reviews but they can also chose to remain anonymous.
|
|
|
|
|
|
|
6.9 CONTROVERSES
|
|
|